Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 In Vitro and In Vivo

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1807-1814

  Khan, Atif J ^a   Wall, Brian ^b   Ahlawat, Stuti ^a   Green, Camille ^a   Schiff, Devora ^a   Mehnert, Janice M ^c   Goydos, James S ^d   Chen, Suzie ^b   Haffty, Bruce G ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c Division of Medical Oncology   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DNA; METABOTROPIC RECEPTOR 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RILUZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL COUNT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SURVIVAL; CHEMORADIOTHERAPY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DNA DAMAGE; DRUG POTENTIATION; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; EXCITATORY AMINO ACID AGENTS; HISTONES; HUMANS; MELANOMA; MICE; MICE, NUDE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECEPTORS, METABOTROPIC GLUTAMATE; RILUZOLE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953316415     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1276     Document Type: Article

References (29)

1. Patchell RA, Regine WF, Loeffler JS, Sawaya R, Andrews DW, Chin LS. Radiosurgery plus whole-brain radiation therapy for brain metastases. JAMA 2006;296:2089-90; author reply 90-1.
2. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280: 1485-9. (Pubitemid 28507400)
3. Broadbent AM, Hruby G, Tin MM, Jackson M, Firth I. Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. Radiother Oncol 2004;71:259-65. (Pubitemid 38686662)
4. McKay M, Kefford R. The spectrum of in vitro radiosensitivity in four human melanoma cell lines is not accounted for by differential induction of rejoining of DNA double strand breaks. Int J Radiat Oncol Biol Phys 1995;31:345-52.
5. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978;42:660-8.
6. Marin YE, Namkoong J, Cohen-Solal K, Shin SS, Martino JJ, Oka M, et al. Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal 2006;18:1279-86. (Pubitemid 43674044)
7. Namkoong J, Shin SS, Lee HJ, Marín YE, Wall BA, Goydos JS, et al. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 2007;67:2298-305. (Pubitemid 46424250)
8. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003;34:108-12. (Pubitemid 36548800)
9. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996;47:S233-41.
10. McGeer EG, McGeer PL. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs 2005;19:31-7. (Pubitemid 40432505)
11. Miller R. Riluzole for ALS: what is the evidence?Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:135.
12. Yip D, Le MN, Chan JL, Lee JH, Mehnert JA, Yudd A, et al. A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 2009;15:3896-902.
13. Habermalz HJ, Fischer JJ. Radiation therapy of malignant melanoma: experience with high individual treatment doses. Cancer 1976;38:2258-62.
14. Ballo MT, Ang KK. Radiation therapy for malignant melanoma. Surg Clin North Am 2003;83:323-42. (Pubitemid 36514812)
15. Ballo MT, Ang KK. Radiotherapy for cutaneous malignant melanoma: rationale and indications. Oncology (Williston Park)2004;18:99-107; discussion 107-10, 113-4.
16. Ballo MT, Garden AS, Myers JN, Lee JE, Diaz EM Jr, Sturgis EM, et al. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?Head Neck 2005;27:718-21.
17. Bonnen MD, Ballo MT, Myers JN, Garden AS, Diaz EM Jr, Gershenwald JE, et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 2004;100:383-9. (Pubitemid 38063649)
18. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004;22:1293-300. (Pubitemid 41079844)
19. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22:2101-7. (Pubitemid 41095143)
20. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003;21:2551-7. (Pubitemid 46606337)
21. Hofmann M, Kiecker F, Wurm R, Schlenger L, Budach V, Sterry W, et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 2006;76:59-64. (Pubitemid 43115761)
22. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005;103:2590-7. (Pubitemid 40800539)
23. Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 2006;107: 1883-90. (Pubitemid 44582959)
24. Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002;128:214-8. (Pubitemid 34280379)
25. Mutter N, Stupp R. Temozolomide: a milestone in neuro-oncology and beyond?Expert Rev Anticancer Ther 2006;6:1187-204.
26. Shin SS, Namkoong J, Wall BA, Gleason R, Lee HJ, Chen S. Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res 2008;21:368-78. (Pubitemid 351678078)
27. Zhu H, Reuhl K, Zhang X, Botha R, Ryan K, Wei J, et al. Development of heritable melanoma in transgenic mice. J Invest Dermatol 1998;110:247-52. (Pubitemid 28144599)
28. Zhu H, Ryan K, Chen S. Cloning of novel splice variants of mouse mGluR1. Brain Res Mol Brain Res 1999;73:93-103.
29. Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol 2009;27:4155-61.